Zydus Life arm signs exclusive US licensing and supply pact for MRI contrast agents
Zydus' agreement with Viwit Pharmaceuticals covers the supply of gadobutrol and gadoterate meglumine injections, widely used in MRI procedures to enhance the visibility of internal organs, blood vessels, and tissues. Shares of Zydus Lifesciences Ltd ended at ₹1,118.50, down by ₹1.65, or 0.15%, on the BSE.
ZYDUSLIFE
BSE
Pharmaceuticals
General
Markets